Kontafarma China Holdings Ltd (1312) AI Stock Analysis

• Market Cap: HK$156.20M
• Dividend Yield: N/A
• Average Volume (3M): 815.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: 10.93%
• EPS Growth: -159.62%
• Country: HK
• Employees: 714
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 5,588,572,000
• 10 Day Avg. Volume: 1,329,600
• 30 Day Avg. Volume: 815,000
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

The overall stock score for Kontafarma China Holdings Ltd is low due to significant financial challenges, including declining revenues, poor profitability, and inconsistent cash flows. The technical analysis suggests some buying interest but remains weak overall. Valuation metrics highlight the ongoing losses and lack of profitability, further impacting the stock's attractiveness.

Kontafarma China Holdings Ltd Business Overview & Revenue Model

Company Description

Tongfang Kontafarma Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs and laboratory related products in Mainland China, Singapore, Taiwan, and the United States. The company operates in Pharmaceutical Business and Fitness Business segments. It also offers chemical drugs and prescribed traditional Chinese medicines; operates fitness centers; operates in the franchise business; and provides consultation services for fitness and health activities. The company trades in laboratory related products; researches and develops medical products; and offers corporate advisory services. As of December 31, 2021, it operated 12 fitness centers and 2 yoga center in Taiwan; and 10 fitness centers in Singapore. The company was formerly known as Allied Cement Holdings Limited and changed its name to Tongfang Kontafarma Holdings Limited in August 2016. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Tongfang Kontafarma Holdings Limited is a subsidiary of China Health Management Investment Limited.

How the Company Makes Money

Kontafarma China Holdings Ltd generates revenue through multiple streams within the health and wellness sectors. The company earns income from the manufacturing and sale of pharmaceutical products and nutritional supplements, which constitute a significant portion of its revenue. Additionally, Kontafarma operates fitness and wellness clubs, where it offers memberships and related services, contributing to its earnings. The company may also engage in partnerships or collaborations with other entities in the health industry to expand its market reach and enhance its revenue. Key factors contributing to its earnings include its strategic positioning in the growing health and wellness market in China and its ability to offer a wide range of products and services catering to consumer health needs.

Kontafarma China Holdings Ltd Financial Statement Overview

Summary

Kontafarma China Holdings Ltd is facing significant financial challenges with declining revenues and persistent profitability issues. The balance sheet reflects a weakening financial position due to continuous losses, and cash flow generation is inconsistent, raising operational and financial risks.

Income Statement

Kontafarma China Holdings Ltd shows declining revenue and profitability. The net profit margin is negative due to consistent net losses, and EBIT margins remain poor. Revenue growth has been negative or stagnant, reflecting challenges in maintaining market share or pricing power.

Balance Sheet

The company's balance sheet indicates moderate leverage with a debt-to-equity ratio that has been manageable, but declining equity due to continuous losses is a concern. The equity ratio suggests moderate reliance on equity financing, but the decreasing total assets are troubling.

Cash Flow

Cash flow performance is weak with erratic operating cash flow and negative free cash flow in recent years. The inability to consistently generate free cash flow raises concerns about the company's capacity to fund operations and growth internally.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
897.52M	809.11M	894.06M	961.09M	1.01B
	Gross Profit
516.16M	471.29M	506.22M	482.89M	555.75M
	EBIT
-42.51M	0.00	-47.06M	-42.56M	40.39M
	EBITDA
-49.93M	76.63M	26.93M	112.18M	156.31M
	Net Income Common Stockholders
-75.54M	-28.84M	-109.74M	-4.55M	-20.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
90.58M	87.66M	142.59M	183.96M	194.79M
	Total Assets
1.59B	1.73B	2.12B	2.56B	2.54B
	Total Debt
297.19M	333.82M	590.72M	728.95M	751.29M
	Net Debt
216.60M	256.16M	468.13M	560.99M	585.48M
	Total Liabilities
625.90M	665.39M	964.16M	1.22B	1.19B
	Stockholders Equity
978.70M	1.06B	1.10B	1.19B	1.21B
Cash Flow		Free Cash Flow
0.00	12.92M	-53.84M	-49.31M	51.02M
	Operating Cash Flow
0.00	37.12M	-2.17M	75.07M	206.93M
	Investing Cash Flow
0.00	144.14M	121.53M	23.24M	-206.12M
	Financing Cash Flow
0.00	-198.81M	-137.33M	-99.80M	19.10M

Kontafarma China Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 57.78 is Neutral, neither overbought nor oversold. The STOCH value of 58.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1312.

Kontafarma China Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1110	70 Outperform	HK$345.70M	7.29	6.61%	5.56%	-3.59%	4.81%
1181	55 Neutral	HK$192.61M	53.14	-8.51%	8.38%	-10.93%	-143.61%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
8143	51 Neutral	HK$127.38M	―	-18.22%	―	-56.16%	62.50%
1312	36 Underperform	HK$156.20M	―	-7.42%	―	10.93%	-159.62%
2E5		€7.02B	4.23	8.19%	4.46%	―	―
1143	47 Neutral	HK$82.99M	10.68	1.60%	―	-4.52%	55.30%

Kontafarma China Holdings Ltd Corporate Events

Kontafarma China Holdings Announces 2025 AGM Agenda

Kontafarma China Holdings Limited has announced its upcoming annual general meeting, scheduled for June 24, 2025, in Hong Kong. The meeting will address several key agenda items, including the adoption of the company’s audited financial statements for 2024, the re-election of directors, the authorization of directors’ fees for 2025, and the re-appointment of BDO Limited as the independent auditor. Additionally, the meeting will consider resolutions to authorize the directors to allot and issue shares, with certain limitations, to enhance the company’s operational flexibility.

Kontafarma China Reschedules 2025 AGM and Adjusts Book Closure Period

Kontafarma China Holdings Limited has announced a rescheduling of its 2025 Annual General Meeting (AGM) and a change in the book closure period. Originally set for June 5, 2025, the AGM will now take place on June 24, 2025, due to administrative reasons. Consequently, the book closure period, initially from May 30 to June 5, 2025, will now be from June 18 to June 24, 2025. This adjustment affects the period during which no share transfers will be registered, impacting shareholders’ eligibility to attend and vote at the AGM.

Kontafarma China Holdings Reports Increased Revenue but Higher Losses in 2024

Kontafarma China Holdings Ltd reported its audited consolidated results for the year ended December 31, 2024, showing a revenue increase to HK$897.5 million from HK$809.1 million in 2023. Despite the revenue growth, the company experienced a net loss of HK$99 million, up from a HK$61.1 million loss the previous year, attributed to increased distribution, selling, and administrative expenses. The announcement highlights the financial challenges faced by the company, impacting its market positioning and raising concerns for stakeholders about the company’s future profitability and operational efficiency.

Kontafarma China Holdings to Review Annual Results and Dividend

Kontafarma China Holdings Limited has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the potential payment of a final dividend, which could impact shareholder returns and reflect the company’s financial health.

Kontafarma China Announces Increased Losses Despite Revenue Growth

Kontafarma China Holdings Ltd has issued a profit warning, projecting a consolidated net loss between HK$79.2 million and HK$118.8 million for FY 2024, a significant increase from the previous year’s loss. The loss is attributed to the absence of a one-off gain from subsidiary disposal and an impairment on intangible assets due to slow recovery in its Taiwan fitness business. Despite this, the company anticipates an increase in overall revenue and gross profit, driven by rising demand for its pharmaceutical products and effective marketing strategies, as well as a rebound in its Singapore fitness business and reduced administrative expenses.